85
Participants
Start Date
September 30, 2005
Primary Completion Date
April 30, 2011
Study Completion Date
July 31, 2012
XL184
Flavored liquid suspension or gelatin capsules supplied in 25-mg and 100-mg strengths; daily dosing or intermittent schedule (daily dosing followed by dosing holiday in cycles)
Memorial Sloan Kettering Cancer Center, New York
Fox Chase Cancer Center, Philadelphia
Johns Hopkins University, Baltimore
University of Chicago, Chicago
Univ. of Texas MD Anderson Cancer Center, Houston
Lead Sponsor
Exelixis
INDUSTRY